Radiotherapy combined with anlotinib for recurrent high-grade soft tissue sarcoma of the scalp: a case report
- 1Department of Oncology, Shangdong Provincial Key Medical and Health Discipline, Qingdao Central Hospital, University of Health and Rehabilitation Sciences
- 2Emergency Center, Qingdao Central Hospital, University of Health and Rehabilitation Sciences
Abstract
Purpose: Soft tissue sarcoma (STS) is a rare but aggressive mesenchymal malignancy that accounts for less than 1% of all adult cancers. Head and neck soft tissue sarcomas (HNSTS) are infrequent malignant tumors arising from mesenchymal and neuroectodermal tissues in the head and neck region with a poor prognosis, and recurrence is predominantly local. There are few targeted management guidelines.
Case description: We report the case of a 77-year-old woman with postoperative recurrence of HNSTS. The patient was diagnosed with high-grade soft tissue sarcoma of the scalp in February 2025 and treated with surgery. In June 2025, the patient was diagnosed with recurrence, and was subsequently treated with combination therapy consisting of the anti-angiogenic inhibitor anlotinib and radiotherapy. In December 2025, after nine cycles, the patient showed a complete response (CR) to therapy.
Conclusion: This indicates that radiotherapy combined with anti-angiogenic targeted therapy may produce synergistic effects in patients with HNSTS and provide directions for future clinical decision-making.
Related
- Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis
- Preoperative Radiotherapy and Local Recurrence in Grade 3 Soft Tissue Sarcoma: A Causal Bayesian Network Analysis
- Clinical outcomes and toxicity after proton- versus photon-based spatially fractionated radiotherapy for soft-tissue sarcoma: a retrospective cohort
- Intensity-modulated radiotherapy combined with albumin-bound paclitaxel and platinum-based chemotherapy for locoregional recurrent cervical cancer: a single-institutional phase II investigator-initiated nonrandomized clinical trial
- Definitive carbon ion radiotherapy for thoracic bone and soft tissue sarcoma
BibTeX
@article{li2026radiotherapy,
title = {{Radiotherapy combined with anlotinib for recurrent high-grade soft tissue sarcoma of the scalp: a case report}},
author = {Bingxuan Li and Jinling Ren and Xiaoxia Song and Xiaogai Qi},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1941568},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1941568/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Radiotherapy combined with anlotinib for recurrent high-grade soft tissue sarcoma of the scalp: a case report
AU - Bingxuan Li
AU - Jinling Ren
AU - Xiaoxia Song
AU - Xiaogai Qi
PY - 2026
DA - 2026/10/14
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1941568
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1941568/full
AB - Purpose: Soft tissue sarcoma (STS) is a rare but aggressive mesenchymal malignancy that accounts for less than 1% of all adult cancers. Head and neck soft tissue sarcomas (HNSTS) are infrequent malignant tumors arising from mesenchymal and neuroectodermal tissues in the head and neck region with a poor prognosis, and recurrence is predominantly local. There are few targeted management guidelines. Case description: We report the case of a 77-year-old woman with postoperative recurrence of HNSTS. The patient was diagnosed with high-grade soft tissue sarcoma of the scalp in February 2025 and treated with surgery. In June 2025, the patient was diagnosed with recurrence, and was subsequently treated with combination therapy consisting of the anti-angiogenic inhibitor anlotinib and radiotherapy. In December 2025, after nine cycles, the patient showed a complete response (CR) to therapy. Conclusion: This indicates that radiotherapy combined with anti-angiogenic targeted therapy may produce synergistic effects in patients with HNSTS and provide directions for future clinical decision-making.
SN - 2234-943X
ER -